محسينس		4.				_					
Substitu	te for	frm 1449	VPTO			App	lication Number	10/762,388			
		SAATI	ON E	Neci As	LIDE	Filin	g Date	January 22, 2004			
				ISCLOS APPLIC		First	Named Inventor	James L. Madara			
314						Art l	Jnit	1614			
•	(US	e as many	SHEEKS	as necessary	,	Exar	miner Name	Unknown			
Sheet		1	of	1		Atto	rney Docket Number	7210.03			
				<u></u>	U.S. PAT	ENT	DOCUMENTS				
•	Cite	2000	UMENT N					Pages, Colu			
*Examiner Initials	No.	H		de (if known)	Publication Date MM-DD-YYYY		Name of Patente Applicant of Cited Do		Where Relevant Passages or Relevant Figures Appear		es or ear
•		US-									
·		US-			_						
		US-									
		US-									
		US-									
		US-									
		US-									
		US-									
		US-									
		US-									
		US-									
		US-				_					
		US-									
		US-						· · · · · · · · · · · · · · · · · · ·			
	 -			FO	REIGN P	ATE	NT DOCUMENTS		<u></u>	_T	
		EODEIG	N DATEN	T DOCUMENT							
		Country	FOREIGN PATENT DOCUMENT Country Number - Kind Code (if		Publicati	ion		Pages, Co	olumns, Lines,	TRANSL	ATION
*Examiner Initial	Cite No.	Code:		known)	Date MM-DD-Y	YYY	Name of Patentee or Applicant of Cited Document		evant Passages Figures Appear	YES	NO
2.5		JP	63-178	325	01-28-19	88	Teijin Ltd.	-	-		
					1		······································				
					1						
				<u> </u>	 			<u> </u>			
					<u> </u>						
							· · · · · · · · · · · · · · · · · · ·				
EXAMI	NER:	SIGNATUF	RE /	colon	For		DATE CONSIDERED	2/1/5	06		
						r not d	citation is in conformance	· /		ine thro	

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	e for	form 1449A	/PTO	3. W. E. o.	35	Appli	cation Number	10/762,388			
INFORMATION DISCESS						Filing	Date	January 22, 2004			
INF	OR	MATIC	ON D	ISCLO	SURE	First Named Inventor		James L. Madara			
STATEMENT BY APPLIC						Art Unit		Unknown			
	(us	e as many	sheets	as necessar	<i>y)</i>	Examiner Name		Unknown			
Sheet	T	 1	of	4		Attor	ney Docket Number	7210.03			
	U.S. PATENT DOCUMENTS										
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)			Publication	ublication Date Name of Patentee or Relev		Relevant Pa	umns, Lines, Where nt Passages or Figures Appear		
z.f			441,951		8-1995	<u> </u>	Serhan	· - · · · · · · · · · · · · · · · · · ·			
26		US- 5,0	648,512	2	7-1997	<u>.</u>	Serhan				
ZiF		US- 6,	353,026	3	3-2002	. 1. 0	Serhan				
Zif		US- 6,	458,839)	10-2002		Madara et al.				
ZG		US- 6,0	699,905	5	3-2004	; **	Madara et al.				
₽ ∴		us-									
				FC	DREIGN F	ATE	NT DOCUMENTS	_			
		FOREIGN PATENT DOCUMENT									
*Examiner Initial	Cite No.	Country Code:		r - Kind Code known)	Publication D	Name of Fateritee of		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		TRANSLA	NO
26	•	PCT	WO 94	1/29262	12-1994						
2.6		PCT	WO 95	5/01179	1-1995						
24		PCT	WO 00	0/54767	9-2000						
,											
		OT	HER I	DOCUMEN	ITS - NON	J-PA1	ENT LITERATUR	E DOCUM	FNTS		
*Examiner	Cite No.		clude nar	ne of the author ook, magazine,	(in CAPITAL l journal, serial,	ETTER:	S), title of the article (when a um, catalog, etc.), date, page	ppropriate), title e(s), volume-iss	of the	TRANSLA	TION
HEUDES	140.	<u> </u>		numb	er(s), publishe	r, city an	d/or country where published	<u> </u>	-	YES	NO
25				Smolen, J. I neutrophils. I			I. M. (1980) Release o 3, 27-34	f inflammato	ory mediators		
							, C. C. (1996) Lipid n EB J. 10, 1147-1158	nediator net	works in cell		
		Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376									Ċ
		Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212, 1-25									
24		Borgeat, P., and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B ₄ . Clin. Biochem. 23, 459-468									

P. 55. P.

Substitute fo	r form 1449A	/PTO		Application Number	10/762,388					
	DN/ATI) NI D	ISCLOSURE	Filing Date	January 22, 2004					
			APPLICANT	First Named Inventor	James L. Madara					
• • • • •			as necessary)	Art Unit	Unknown					
"	oc as many		ao nooossary)	Examiner Name	Unknown					
Sheet	2	of	4	Attorney Docket Number	7210.03					
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
2.6	Yokomizo receptor f	o, T., Iz or leuk	zumi, T., Chang, K., T. otriene B ₄ that mediate	akuwa, T., and Shimizu, T. (1 s chemotaxis. <i>Nature</i> 387, 620	997) A G-protein-coupled -624					
		Fiore, S., Romano, M., Reardon, E. M., and Serhan, C. N. (1993) Induction of functional lipoxin A ₄ receptors in HL-60 cells. <i>Blood</i> 81, 3395-3403								
		of a b		l., Salvemini, D., Lee, L., ar in Prostaglandin, Thromboxar						
	triggered	Chiang, N., Takano, T., Clish, C. B., Petasis, N. A., Tai, HH., and Serhan, C. N. (1998) Aspirintriggered 15-epi-lipoxin A ₄ (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA ₄ ELISA. <i>J. Pharmacol Exper. Ther.</i> 287, 779-790								
	R., Colga	Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A₄ stable analogs that block transmigration and adhesion of human neutrophils. <i>Biochemistry</i> 34, 14609-14615								
	Aspirin-tri	Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A ₄ (LXA ₄) and LXA ₄ Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. <i>J. Exp. Med.</i> 185, 1693-1704								
	leukotrien	Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A., and Gallo, R. (1998) The leukotriene B ₄ receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. <i>Proc. Natl. Acad. Sci.</i> 95, 9530-9534								
	Marcus, A	Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333, 656-								
		Vainio, H., and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. <i>Pharmacol Toxicol</i> 81, 151-152								
		Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. <i>Trends in Cardiovasc. Med.</i> 8, 145-150								
	changes	Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epilipoxin A ₄ and novel lipoxin B ₄ stable analogues. <i>J. Clin. Invest.</i> 101, 819-826								
	Phosphat levels in	Billah, M. M., Eckel, S., Mullmann, T. J., Egan, R. W., and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phosphatidate phosphohydrolase in signal transduction. <i>J. Biol. Chem.</i> 264, 17069-17077								
ZIF	P. G., and	d Reyn		, M. N., Brown, F., Pettit, T. R and regulation of phospholipa ulation 37, 29-34						
	cancer ce	ells. Ad	vances in Enzyme Reg	ulation 37, 29-34		L	<u> </u>			

1- "

Substi	tute to	r form 1449A	/10		Application Number	10/762,388				
INI	FΩI	RMATIC)N L	ISCLOSURE	Filing Date	January 22, 2004				
				APPLICANT	First Named Inventor	James L. Madara				
51				as necessary)	Art Unit	Unknown				
	(0				Examiner Name	Unknown				
Shee	t	3	of	4	Attorney Docket Number	7210.03				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
2.F				d Lambeth, J. D. (1996) ils. <i>Chem. Phys. Lipids</i> 8	liochemistry and cell biology of phospholipase D in D, 3-19					
			Steed, P. M., Clark, K. L., Boyar, W. C., and Lasala, D. J. (1998) Characterization of human PLD2 and the analysis of PLD isoform splice variants. <i>FASEB J.</i> 12, 1309-1317							
			, M. J.	O. (1997) Role and regu	Brown, F. D., Pettit, T. R., Arr lation of phospholipase D sign					
				asis, N. A., and Serhan, (e 389, 985-989	C. N. (1997) Polyisoprenyl ph	osphates in intracellular				
		acid as a	Agwu, D. E., McPhail, L. C., Sozzani, S., Bass, D. A., and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. <i>J. Clin. Invest.</i> 88, 531-539							
		Diacylglyd	Pettit, T. R., Martin, A., Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. <i>J. Biol. Chem.</i> 272, 17354-17359							
			Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. <i>J. Interferon Cytokine Res.</i> 15, 877-885							
			Abousalham, A., Riviere, M., Teissere, M., and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage. <i>Biochim. Biophys. Acta</i> 1158, 1-7							
		Torphy, T	Zhou, HL., Chabot-Fletcher, M., Foley, J. J., Sarau, H. M., Tzimas, M. N., Winkler, J. D., and Torphy, T. J. (1993) Association between leukotriene B ₄ -induced phospholipase D activation and degranulation of human neutrophils. <i>Biochem. Pharmacol.</i> 46, 139-148							
,			Shechter, I., Fogelman, A. M., and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. <i>J. Lipid Res.</i> 21, 277-							
		Rabinowi lipid profil	tz, J. L. es of a	., Baker, D. G., Villanuev dults taking therapeutic o	a, T. G., Asanza, A. P., and C doses of aspirin. <i>Lipids</i> 27, 31	capuzzi, D. M. (1992) Liver 1-314				
			Claria, J., and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci.</i> 92, 9475-9479							
		Serhan, C Interaction	C. N. (1 ns or a	997) Lipoxins and Novel Therapeutic Opportunity	Aspirin-Triggered 15-epi-Lipo Prostaglandins 53, 107-137	exins: A Jungle of Cell-Cell				
		Exton, J.	H. (199	97) New developments ir	n phospholipase D. <i>J. Biol. Ch</i>	em. 272, 15579-15582				
2.4		factor and	i Rho p	hatmore, J., Morgan, C., proteins mediate fMLP-de iol. Chem. 273, 13157-1	Jones, D., and Cockcroft, S. ependent activation of phosph 3164	(1998) ADP-ribosylation olipase D in human				

* * .

Substitut	e for	form 1449A/	/PTO		Application Number	10/762,388				
INIEC)DI		M DI	ISCLOSURE	Filing Date	January 22, 2004				
				APPLICANT	First Named Inventor	James L. Madara	James L. Madara			
					Art Unit	Unknown				
(US U as	Maii	ny sheets as	5 /16063	3Sary) 	Examiner Name	Unknown	Unknown			
Sheet	\prod	4	of	4	Attorney Docket Number	7210.03	7210.03			
OTHE	RD	OCUMEI	NTS -	NON-PATENT LITE	RATURE DOCUMENTS	š				
2,6		squalene.	. Evider	nce for a tertiary cyclopro	D. H., and Poulter, C. D. (1996 opylcarbinyl cationic intermed J. Amer. Chem. Soc. 118, 13	liate in the rearrangement				
		Bach, T. J 191-202	Bach, T. J. (1995) Some new aspects of isoprenoid biosynthesis in plantsa review. <i>Lipids</i> 30,							
		Neutrophi	Serhan et al., "Aspirin-Triggered 15-EPI-Lipoxin A₄ and Novel Lipoxin B₄ Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability," <i>Advances in Experimental Medicine and Biology</i> , Vol. 469, 1999, pgs. 287-293							
		Inhibited b	Gewirzt et al., "Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A ₄ Analogs", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 9, May 1998, pgs. 1860-1869							
		intracellul	Hansson et al., "Activation of Protein Kinase C By Lipoxin A and Other Eicosandoids. Intracellular Action of Oxygenation Products of Arachidonic Acid", <i>Biochemical and Biophysical Research Communications</i> , Vol. 134, No. 3, 1986, pgs. 1215-1222							
			Olson et al., "Biochemistry and cell biology of phospholipase D in human neutrophils", Chemistry and Physics of Lipids, 80, pp. 3-19, 1996							
Zif		Takano et al., "Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A4 and Novel Lipoxin B4 Stable Analogues", J. Clin. Invest. Volume 101, Number 4, February 1998, pp. 819-826								
EXAMIN	IER :	SIGNATURI	E Z	about For	DATE CONSIDERED	2/1/06				
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through									

: · ·

Er W

ere and a second

•.

copy of this form with next communication to applican